Partow Kebriaei, M.D.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
About Dr. Partow Kebriaei
Dr. Kebriaei received her B.S. degree from Yale University in 1993, and her M.D. degree from the University of Texas at Houston medical school in 1997. She went on to receive her Internal Medicine training at University of Texas Southwestern in Dallas, and completed a fellowship in Hematology and Oncology at the University of Chicago in 2000. She joined the stem cell transplant department at MD Anderson Cancer Center (MDACC) in 2003. Dr. Kebriaei’s research interests include therapy of leukemias, in particular acute lymphoblastic leukemia (ALL), and she has led the development of the transplant program in ALL. She is also interested in the development of novel transplant preparative regimens that may have less regimen-related toxicity, and increased disease efficacy. More specifically, she is interested in investigating the use of traditional chemotherapeutic agents in combination with cellular therapies and adoptive immunotherapy to develop more effective treatment regimens. Work toward this aim includes investigating the use CD19-directed T cell therapy for lymphoid malignancies, and investigating the use of mesenchymal stromal cells for the therapy of graft versus host disease. Finally, she has been involved in the development of the CARTOX committee, a cross-disciplinary committee to oversee the safe administration of cellular therapy treatments. Dr. Kebriaei is actively involved in current phase I/II clinical trials at MDACC, has authored numerous reviews, book chapters, and papers, and serves as a reviewer for major hematology and oncology publications. She is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Blood and Marrow Transplantation.
Present Title & Affiliation
Primary Appointment
Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1997 | The University of Texas Health Science Center, Houston, TX, USA, MD, Medicine |
| 1993 | Yale University, New Haven, CT, USA, BS, Biology |
Postgraduate Training
| 2000-2003 | Hematology/Oncology Fellowship, Everett Vokes, M.D, University of Chicago Medical Center, Chicago, IL |
| 1998-2000 | Internal Medicine Residency, Daniel W. Foster, M.D, University of Texas Southwestern Medical Center, Dallas, TX |
| 1997-1998 | Internal Medicine Internship, Daniel W. Foster, M.D, University of Texas Southwestern Medical Center, Dallas, TX |
Board Certifications
| 2004 | Hematology |
| 2003 | Medical Oncology |
| 2001 | Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2015
Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2009
Administrative Appointments/Responsibilities
Cancer Medicine Director, Cancer Network, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Clinic Medical Director, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Other Appointments/Responsibilities
CPSS Messenger Council, Center of Professionalism, Support and Success (CPSS), Houston, 2024 - 2024
Wellness Champions, SCT department, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2024
Member Executive Committee Faculty Senate (ECFS), University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2024
Division Professionalism Ambassador (DPA), Center of Professionalism, Support and Success (CPSS), Houston, TX, 2022 - Present
Member, Center International Blood and Marrow Transplant Research, Resource for clinical investigation in blood and marrow transplantation (CIBMTR RCI BMT) Data Safety Monitoring Board (DSMB), Philadelphia, PA, 2022 - 2025
SCT/CT Department Mentoring Committee Member, University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Co-Chair of Acute Leukemia Working Committee, Center for International Blood and Marrow Transplant Research, Houston, TX, 2019 - 2024
Member, CIDR Executive Council Member, Center for International Blood and Marrow Transplant Research, Houston, TX, 2019 - 2022
Committee Member Lymphoma/Myeloma faculty recruitment, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Member, National Marrow Donor Program Institutional Review Board, Houston, TX, 2018 - Present
Lead Workgroup Physician, Scripps/MD Anderson Collaboration, Houston, TX, 2018 - Present
Mentor, Division of Pediatrics Faculty Career Mentoring Program, Houston, TX, 2018 - Present
Faculty Mentor, Clinical Research Training Course, Center for International Blood and Marrow Transplant Research, Houston, TX, 2017 - Present
Lead, Data Group, CARTOX Committee, University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Institutional Committee Activities
Member, Faculty Senate, 2018 - Present
Member, Credentials Committee, 2018 - 2020
Member, CARTOX Committee, 2017 - Present
Member, Institutional Pre-Recombinant Advisory Committee, 2016 - Present
Chairperson, Acute & Critical Care Subcommittee, 2012 - Present
Chairperson, Intensive Care Unit Committee, 2010 - 2012
Member, Medical Practice Committee, 2010 - Present
Associate Member, Institutional Review Board 5, 2008 - 2012
Chairperson, Clinical Research Committee I, 2008 - 2011
Member, Medical Records Committee, 2008 - Present
Member, Council of Committee Chairs, 2007 - Present
Member, Clinical Research Committee 3, 2006 - 2007
Honors & Awards
| 2021 | The Presidents’ Recognition of Faculty Excellence: Faculty Honoree for Education and Mentorship Advancement, University of Texas MD Anderson Cancer Center |
| 2021 | FY21 Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center |
| 2019 | Waun Ki hong Award for Excellence in Team Science in ALL, University of Texas MD Anderson Cancer Center |
| 2017 | Waun Ki Hong Award for Excellence in Team Science in CAR T Therapy, University of Texas MD Anderson Cancer Center |
| 2011 | Mid-Career Women Faculty Professional Development, Women Faculty Programs, University of Texas MD Anderson Cancer Center |
| 2003 | Merit Award, American Society of Clinical Oncology |
| 2002 | Molecular Biology Workshop, American Association for Cancer Research |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin DC, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation. Blood Adv. e-Pub 2024. PMID: 38266155.
- Rahman ZA, Kebriaei P. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023. Clin Lymphoma Myeloma Leuk 23(11):779-785, 2023. e-Pub 2023. PMID: 37438208.
- Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies. Transplant Cell Ther 29(4):228-239, 2023. e-Pub 2023. PMID: 36709800.
- Mehta RS, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Weisdorf D, Kebriaei P. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv 7(8):1594-1603, 2023. PMID: 36630564.
- Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2022. PMID: 36502492.
- Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. Blood 140(20):2101-2112, 2022. e-Pub 2022. PMID: 35877996.
- Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
- Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol 13:1032397, 2022. e-Pub 2022. PMID: 36439104.
- Gaballa MR, Banerjee PP, Milton DR, Jiang X, Ganesh C, Khazal SJ, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta RS, Alatrash G, Khouri IF, Oran B, Marin D, Popat UR, Olson AL, Tewari P, Jain N, Jabbour EJ, Ravandi F, Kantarjian HM, Chen K, Champlin RE, Shpall EJ, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood. e-Pub 2021. PMID: 34914826.
- Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
- Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia 35(7):2076-2085, 2021. e-Pub 2021. PMID: 33785862.
- Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. PMID: 34264268.
- Pasvolsky O, Daher M, Alatrash G, Marin D, Daver N, Ravandi F, Rezvani K, Shpall E, Kebriaei P. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Front Oncol 11:800110, 2021. e-Pub 2022. PMID: 35083154.
- Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
- Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G, Hong DS, Shpall EJ, Kebriaei P. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biol Blood Marrow Transplant 26(10):1759-1769, 2020. e-Pub 2020. PMID: 32623078.
- Muffly L, Kebriaei P. Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020. Semin Hematol 57(3):137-141, 2020. e-Pub 2020. PMID: 33256903.
- Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, Waller EK, Burke E, Skerrett D, Shpall E, Martin PJ. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 26(5):835-844, 2020. e-Pub 2019. PMID: 31505228.
- Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty generated CD19specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
- Mahadeo KM, Bajwa R, Abdel-Azim H, Lehmann LE, Duncan C, Zantek N, Vittorio J, Angelo J, McArthur J, Schadler K, Chan S, Tewari P, Khazal S, Auletta JJ, Choi SW, Shoberu B, Kalwak K, Harden A, Kebriaei P, Abe JI, Li S, Moffet JR, Abraham S, Tambaro FP, Kleinschmidt K, Richardson PG, Corbacioglu S, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network and the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol 7(1):e61-e72, 2020. e-Pub 2019. PMID: 31818728.
- DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(11):2113-2123, 2019. e-Pub 2019. PMID: 31446198.
- Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 16(1):45-63, 2019. e-Pub 2018. PMID: 30082906.
- Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Adv 2(17):2254-2261, 2018. PMID: 30206098.
- Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2018. PMID: 29769261.
- Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI, Acute Leukemia Committee of the CIBMTR. Intravenous Busulfan Compared to Total Body Irradiation Pre-Transplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 24(4):726-733, 2018. e-Pub 2017. PMID: 29197676.
- Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant 53(4):449-456, 2018. e-Pub 2018. PMID: 29330398.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. e-Pub 2017. PMID: 28925994.
- Kebriaei P, Izsvák Z, Narayanavari SA, Singh H, Ivics Z. Gene Therapy with the Sleeping Beauty Transposon System. Trends Genet 33(11):852-870, 2017. e-Pub 2017. PMID: 28964527.
- Perales MA, Kebriaei P, Kean LS, Sadelain M. Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biol Blood Marrow Transplant. e-Pub 2017. PMID: 29032264.
- Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei P. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma 58(2):1-6, 2017. e-Pub 2016. PMID: 27348707.
- Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2016. PMID: 27816651.
- Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 23(2):318-324, 2017. e-Pub 2016. PMID: 27856368.
- Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei P. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant 52(1):20-27, 2017. e-Pub 2016. PMID: 27618682.
- Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
- Kebriaei P, Poon ML. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)-Potential Role of Immune-Based Therapies. Curr Hematol Malig Rep 10(2):76-85, 2015. PMID: 25899862.
- Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei P. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant 50(4):493-8, 2015. e-Pub 2015. PMID: 25621808.
- Hamdi A, Mawad R, Bassett R, di Stasi A, Ferro R, Afrough A, Ram R, Dabaja B, Rondon G, Champlin R, Sandmaier BM, Doney K, Bar M, Kebriaei P. Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(11):1767-71, 2014. e-Pub 2014. PMID: 25017763.
- Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257(1):181-90, 2014. PMID: 24329797.
- Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, Worth L, O'Brien S, Thomas D, Champlin RE, Kantarjian H. Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk 13(3):296-301, 2013. e-Pub 2013. PMID: 23313065.
- Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-26, 2012. e-Pub 2012. PMID: 22750645.
- Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23(5):444-50, 2012. e-Pub 2012. PMID: 22107246.
- Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biol Blood Marrow Transplant 18(4):584-92, 2012. e-Pub 2011. PMID: 21867666.
- Kebriaei P, Simon R. Mesenchymal Stem Cell Therapy in the Treatment of Acute and Chronic Graft versus Host Disease. Frontiers in Hematology Oncology 1:1-8, 2011.
- Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 2011. e-Pub 2010. PMID: 20674757.
- Kebriaei P, Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 13(3):262-8, 2011. e-Pub 2011. PMID: 21231805.
- Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 15(7):804-11, 2009. PMID: 19539211.
Invited Articles
- Tewari P, Kebriaei P. Hematopoetic Stem Cell Transplantation in Adolescents and Young Adults. Acta Haematologica 132(3-4):313-325, 2014.
- Kebriaei P, Kelly SS, Manuri P, Jena B, Jackson R, Shpall E, Champlin R, Cooper LJ. Chimeric antibody receptors (CARs): Driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed) 4:520-31, 2012. e-Pub 2012. PMID: 22202074.
- Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23(5):1043-63, vi, 2009. PMID: 19825452.
Editorials
- Kebriaei P. Mesenchymal Stromal Cells The magic Band-Aid. Acta Haematol 133(1):70-71, 2015. PMID: 25139435.
- Ravandi F, Kebriaei P, . Treatment for Adult ALL. International Journal of Hematology and Oncology 2(1):5-8, 2013.
Book Chapters
- Kebriaei P, Ravandi F, De Lima M, Champlin R. Management of Acute Leukemias in Cancer. In: Principles and Practice of Oncology. 12th. De Vita, Hellman, Rosenberg, 2023.
- Poon M, Champlin R, Kebriaei P. Principles of Hematopoietic. In: Principles and Practice of Transplant Infectious Diseases. Springer Publications: New York, 153-163, 2019.
- Poon Limei M, Kebriaei P. Hematopoietic Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia (Excluding Ph+ ALL). In: Current Concepts and Controversies in Hematopoietic Cell Transplantation. Cambridge University, 144-152, 2012.
Grant & Contract Support
| Date: | 2021 - 2026 |
| Title: | Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) And Myelodysplasia-Excess Blasts (MDS-EB) |
| Funding Source: | Magenta Therapeutics |
| Role: | Principal Investigator |
| ID: | #60266 |
| Date: | 2018 - 2023 |
| Title: | Novel Cord Blood Derived Cellular Therapies |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | 5P01CA148600-11 |
| Date: | 2017 - 2023 |
| Title: | A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation vs Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia |
| Funding Source: | Actinium Pharmaceuticals |
| Role: | Principal Investigator |
| ID: | 52529 |
| Date: | 2016 - 2023 |
| Title: | Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia |
| Funding Source: | Amgen Pharmaceutical |
| Role: | Principal Investigator |
| ID: | 5117 |
Patient Reviews
CV information above last modified August 12, 2024